FILANA THERAPEUTICS, INC. — Form 8-K
Filed July 29, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Filana Therapeutics reported Q2 2026 results with cash declining from $95.5M (Dec 2025) to $82.7M (Jun 2026). The company paid $31.25M into escrow on July 23, 2026 for securities litigation settlement (recorded as contingency in 2025). Core development: the FDA clinical hold on simufilam proof-of-concept trial for TSC-related epilepsy remains in place; company is working to address FDA information requests to lift the hold. R&D expenses decreased 35% to $3.3M (Q2 2026 vs. $5.1M Q2 2025) following Alzheimer's program phase-out in Q2 2025.
Why this rating
Clinical hold blocks lead program and regulatory pathway; litigation settlement consumes 36% of cash ($31.25M of $87M market cap). Runway pressured but not imminent crisis at $36-40M projected year-end cash.
See more from July 29, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.